- Home
- RPRX vs AKAM Comparison
RPRX vs AKAM Comparison
Compare RPRX & AKAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- AKAM
- Stock Information
- Founded
- RPRX 1996
- AKAM 1998
- Country
- RPRX United States
- AKAM United States
- Employees
- RPRX N/A
- AKAM N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- AKAM Business Services
- Sector
- RPRX Health Care
- AKAM Consumer Discretionary
- Exchange
- RPRX Nasdaq
- AKAM Nasdaq
- Market Cap
- RPRX 14.2B
- AKAM 12.2B
- IPO Year
- RPRX 2020
- AKAM 1999
- Fundamental
- Price
- RPRX $31.11
- AKAM $73.69
- Analyst Decision
- RPRX Strong Buy
- AKAM Buy
- Analyst Count
- RPRX 5
- AKAM 22
- Target Price
- RPRX $41.60
- AKAM $109.45
- AVG Volume (30 Days)
- RPRX 4.6M
- AKAM 2.2M
- Earning Date
- RPRX 05-08-2025
- AKAM 05-08-2025
- Dividend Yield
- RPRX 2.83%
- AKAM N/A
- EPS Growth
- RPRX N/A
- AKAM N/A
- EPS
- RPRX 1.91
- AKAM 3.27
- Revenue
- RPRX $2,263,576,000.00
- AKAM $3,991,168,000.00
- Revenue This Year
- RPRX $34.04
- AKAM $5.18
- Revenue Next Year
- RPRX $6.10
- AKAM $5.81
- P/E Ratio
- RPRX $16.29
- AKAM $22.54
- Revenue Growth
- RPRX N/A
- AKAM 4.70
- 52 Week Low
- RPRX $24.05
- AKAM $73.42
- 52 Week High
- RPRX $34.20
- AKAM $107.60
- Technical
- Relative Strength Index (RSI)
- RPRX 37.21
- AKAM 29.81
- Support Level
- RPRX $30.82
- AKAM $78.36
- Resistance Level
- RPRX $31.85
- AKAM $81.99
- Average True Range (ATR)
- RPRX 0.80
- AKAM 1.93
- MACD
- RPRX -0.24
- AKAM -0.13
- Stochastic Oscillator
- RPRX 17.89
- AKAM 2.76
Stock Price Comparison Chart: RPRX vs AKAM
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About AKAM Akamai Technologies Inc.
Akamai operates a content delivery network, which entails locating servers at the edges of networks so its customers, which store content on Akamai servers, can reach their own customers faster, more securely, and with better quality. Akamai has over 325,000 servers distributed over 4,100 points of presence in more than 1,000 cities worldwide. The firm also offers security and cloud computing for its customers, and those businesses have grown to be bigger than the legacy CDN.